155 related articles for article (PubMed ID: 37181949)
1. Frequency of Hepatic Metastatic Disease in Patients with Stage IV Breast Cancer Is Similar for Steatotic and Non-Steatotic Livers.
Haq A; Fraum TJ; Tao Y; Dehdashti F; LeBlanc M; Hoegger MJ; Luo J; Weilbaecher K; Peterson LL
Breast Cancer (Auckl); 2023; 17():11782234231166476. PubMed ID: 37181949
[TBL] [Abstract][Full Text] [Related]
2. Liver Enhancement on Computed Tomography Is Suboptimal in Patients with Liver Steatosis.
van Cooten VV; de Jong DJ; Wessels FJ; de Jong PA; Kok M
J Pers Med; 2021 Nov; 11(12):. PubMed ID: 34945727
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
4. Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer.
Murono K; Kitayama J; Tsuno NH; Nozawa H; Kawai K; Sunami E; Akahane M; Watanabe T
Int J Colorectal Dis; 2013 Aug; 28(8):1065-72. PubMed ID: 23392476
[TBL] [Abstract][Full Text] [Related]
5. Hepatic steatosis is associated with higher incidence of liver metastasis in patients with metastatic breast cancer; an observational clinical study.
Ocak Duran A; Yildirim A; Inanc M; Karaca H; Berk V; Bozkurt O; Ozaslan E; Ucar M; Ozkan M
J BUON; 2015; 20(4):963-9. PubMed ID: 26416044
[TBL] [Abstract][Full Text] [Related]
6. Decoy receptor 3 analogous supplement protects steatotic rat liver from ischemia-reperfusion injury.
Li TH; Liu CW; Lee PC; Huang CC; Lee KC; Hsieh YC; Yang YY; Hsieh SL; Lin HC; Tsai CY
J Chin Med Assoc; 2017 Jul; 80(7):391-400. PubMed ID: 28325574
[TBL] [Abstract][Full Text] [Related]
7. [The effect of steatotic donor livers on the prognosis of donors and recipients after pediatric living donor liver transplantation].
Yang Y; Dong C; Sun C; Wang K; Zhang W; Zheng WP; Zhang FB; Qin H; Han C; Wang Z; Xu M; Gao W
Zhonghua Wai Ke Za Zhi; 2022 Oct; 60(10):922-929. PubMed ID: 36207981
[No Abstract] [Full Text] [Related]
8. Quantification of hepatic steatosis: a comparison of computed tomography and magnetic resonance indices in candidates for living liver donation.
Maruzzelli L; Parr AJ; Miraglia R; Tuzzolino F; Luca A
Acad Radiol; 2014 Apr; 21(4):507-13. PubMed ID: 24594420
[TBL] [Abstract][Full Text] [Related]
9. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic factors associated with de novo metastatic breast cancer.
Shen T; Siegal GP; Wei S
Pathol Res Pract; 2016 Dec; 212(12):1167-1173. PubMed ID: 27692496
[TBL] [Abstract][Full Text] [Related]
11. Brain metastasis in de novo stage IV breast cancer.
He Y; Shao Y; Chen Q; Liu C; Zhu F; Liu H
Breast; 2023 Oct; 71():54-59. PubMed ID: 37499376
[TBL] [Abstract][Full Text] [Related]
12. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.
Wu SG; Li H; Tang LY; Sun JY; Zhang WW; Li FY; Chen YX; He ZY
Tumour Biol; 2017 Jun; 39(6):1010428317705082. PubMed ID: 28653887
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
14. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
[TBL] [Abstract][Full Text] [Related]
15. Material density hepatic steatosis quantification on intravenous contrast-enhanced rapid kilovolt (peak)-switching single-source dual-energy computed tomography.
Patel BN; Kumbla RA; Berland LL; Fineberg NS; Morgan DE
J Comput Assist Tomogr; 2013; 37(6):904-10. PubMed ID: 24270112
[TBL] [Abstract][Full Text] [Related]
16. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S
AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491
[TBL] [Abstract][Full Text] [Related]
17. Clinical information and management status of de novo stage IV breast cancer patients: a Chinese multicenter investigation (CSBrS-002).
Zheng A; Guo BL; Zhang JG; Jin F;
Chin Med J (Engl); 2021 Jun; 134(13):1569-1575. PubMed ID: 34101635
[TBL] [Abstract][Full Text] [Related]
18. Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases.
Pathak S; Tang JM; Terlizzo M; Poston GJ; Malik HZ
Eur J Surg Oncol; 2010 Jan; 36(1):52-7. PubMed ID: 19879103
[TBL] [Abstract][Full Text] [Related]
19. A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates.
Plichta JK; Thomas SM; Sergesketter AR; Greenup RA; Rosenberger LH; Fayanju OM; Kimmick G; Force J; Hyslop T; Hwang ES
Ann Surg; 2022 Apr; 275(4):784-792. PubMed ID: 32657941
[TBL] [Abstract][Full Text] [Related]
20. May an incidental finding on chest CT be a predictor of access in intensive care unit? Role of hepatic steatosis in patients affected by SARS-CoV-2.
Danna PSC; Buoni GF; Bor S; Coda C; Abruzzese F; Bertoli M; Giaivia V; Airoldi C; Castello LM; Saba L; Carriero A
J Public Health Res; 2022 Oct; 11(4):22799036221115779. PubMed ID: 36407057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
